Advanced search
Publication Cover
Leukemia & Lymphoma Volume 56, 2015 - Issue 5
Submit an article Journal homepage
501
Views
3
CrossRef citations to date
0
Altmetric
Letter to the Editor

Bendamustine in relapsed/refractory multiple myeloma: the “real-life” side of the moon

Pellegrino MustoScientific Direction, IRCCS-CROB, Centro di Riferimento Oncologico della Basilicata, Rionero in Vulture, ItalyCorrespondence[email protected]
,
Vincenzo Ludovico FraticelliOnco-Hematology, Fondazione di Ricerca e Cura “Giovanni Paolo II”, Campobasso, Italy
,
Giovanna MansuetoHematology and SCT Unit, IRCCS-CROB, Centro di Riferimento Oncologico della Basilicata, Rionero in Vulture, Italy
,
Emanuela MadonnaDivision of Hematology, Federico II University, Naples, Italy
,
Andrea NozzaDepartment of Oncology and Hematology, Humanitas Cancer Center, Milan, Italy
,
Alessandro AndrianiUnit of Hematology, Nuovo Regina Margherita Hospital, Rome, Italy
,
Alberto MussettiDepartment of Hematology, Fondazione IRCCS Istituto Nazionale dei Tumori and University of Milan, Milan, Italy
,
Stelvio BallantiSection of Hematology and Clinical Immunology, Silvestrini S. Maria della Misericordia Hospital, Perugia, Italy
,
Velia BongarzoniDepartment of Hematology, S. Giovanni-Addolorata Hospital, Rome, Italy
,
Anna BaraldiUnit of Hematology and SCT, SS Antonio e Biagio and C. Arrigo Hospital, Alessandria, Italy
,
Francesca PatriarcaHematology Clinic, Azienda Ospedaliera-Universitaria, Udine, Italy
,
Donatella VincelliUnit of Hematology and SCT, Bianchi-Melacrino-Morelli Hospital, Reggio Calabria, Italy
,
Antonietta FalconeUnit of Hematology and SCT, IRCCS Casa Sollievo della Sofferenza Hospital, S. Giovanni Rotondo, Italy
,
Daniele DerudasHematology and SCT Unit A. Businco Regional Oncology Hospital, Cagliari, Italy
,
Catello CalifanoDepartment of Oncology, Hematology and Internal Medicine, Andrea Tortora Hospital, Pagani-Nocera, Italy
,
Renato ZambelloDepartment of Clinical and Experimental Medicine, University of Padova, Padova, Italy
,
Giuseppe MeleHematology and SCT Unit, Antonio Perrino Hospital, Brindisi, Italy
,
Alberto FragassoUnit of Hematology, Madonna delle Grazie Hospital, Matera, Italy
,
Luca BaldiniHematology and SCT Unit, Fondazione IRCCS Ca Granda, OM Policlinico, Milan, Italy
&
Sergio StortiOnco-Hematology, Fondazione di Ricerca e Cura “Giovanni Paolo II”, Campobasso, Italy;Institute of Hematology, Catholic University Sacred Heart, Rome, Italy
 show all
Pages 1510-1513 | Received 01 Sep 2014, Accepted 25 Oct 2014, Published online: 03 Mar 2015

References

  • Lentzsch S. Bendamustine: the remedy that came in from the cold. Blood 2014;123:948–950.
  • Palumbo A, Offidani M, Patriarca F, et al. Bendamustine for the treatment of multiple myeloma in first-line and relapsed-refractory settings: a review of clinical trial data. Leuk Lymphoma 2014 Jun 27. [Epub ahead of print]
  • Mele G, Spina A, Guaragna G, et al. Activity and toxicity profiles of the combinations bendamustine-lenalidomide-dexamethasone and bendamustine-bortezomib-dexamethasone for advanced stage multiple myeloma. Leuk Lymphoma 2014;55:1191–1193.
  • Durie BG, Harousseau JL, Miguel JS, et al. International uniform response criteria for multiple myeloma. Leukemia 2006;20:1467–1473.
  • Damaj G, Malard F, Hulin C, et al. Efficacy of bendamustine in relapsed/refractory myeloma patients: results from the French compassionate use program. Leuk Lymphoma 2012;53:632–634.
  • Offidani M, Corvatta L, Maracci L, et al. Efficacy and tolerability of bendamustine, bortezomib and dexamethasone in patients with relapsed-refractory multiple myeloma: a phase II study. Blood Cancer J 2013;3:e162.
  • Ludwig H, Kasparu H, Leitgeb C, et al. Bendamustine-bortezomib-dexamethasone is an active and well-tolerated regimen in patients with relapsed or refractory multiple myeloma. Blood 2014;123:985–991.
  • Pönisch W, Bourgeois M, Moll B, et al. Combined bendamustine, prednisone and bortezomib (BPV) in patients with relapsed or refractory multiple myeloma. J Cancer Res Clin Oncol 2013;139: 499–508.
  • Berenson JR, Yellin O, Bessudo A, et al. Phase I/II trial assessing bendamustine plus bortezomib combination therapy for the treatment of patients with relapsed or refractory multiple myeloma. Br J Haematol 2013;160:321–330.
  • Pönisch W, Heyn S, Beck J, et al. Lenalidomide, bendamustine and prednisolone exhibits a favourable safety and efficacy profile in relapsed orrefractory multiple myeloma: final results of a phase 1 clinical trial OSHO- #077. Br J Haematol 2013;162:202–209.
  • Lentzsch S, O’Sullivan A, Kennedy RC, et al. Combination of bendamustine, lenalidomide, and dexamethasone (BLD) in patients with relapsed or refractory multiple myeloma is feasible and highly effective: results of phase 1/2 open-label, dose escalation study. Blood 2012;119:4608–4613.
  • Grey-Davies E, Bosworth JL, Boyd KD, et al. Bendamustine, thalidomide and dexamethasone is an effective salvage regimen for advanced stage multiple myeloma. Br J Haematol 2012;156:552–555.
  • Highsmith KN, Chen SE, Horowitz S. Carfilzomib and pomalidomide: recent advances in the treatment of multiple myeloma. Pharmacotherapy 2014;34:927–40.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.